Review [inpr]
Raloxifene [orch, phsu]
Profile [lbpr]
Selective Estrogen Receptor Modulator [horm, phsu]
Raloxifene [orch, phsu]
Selective Estrogen Receptor Modulator [horm, phsu]
Approved [qlco]
Prevention [topp]
treatment [ftcn]
Osteoporosis [dsyn]
postmenopausal [tmco]
Women [popg]
Raloxifene [orch, phsu]
Estrogen Effect [fndg]
agonists [phsu]
Bone [bpoc]
Effect [qlco]
Proven [qlco]
Raloxifene [orch, phsu]
Decrease [qlco]
Levels [qlco]
bone markers [medd]
formation [biof]
bone markers [medd]
Resorption [orgf]
postmenopausal [tmco]
Women [popg]
Bone Mineral Density [clna]
Most [qnco]
skeletal [bdsy]
Sites [spco]
Women [popg]
Raloxifene [orch, phsu]
Decrease [qlco]
Serum [bdsu]
Level [qlco]
Low Density Lipoprotein Cholesterol [bacs, strd]
Total Cholesterol [lbpr]
In [qnco]
Breast tissue [bpoc]
Raloxifene [orch, phsu]
Estrogen antagonist [phsu]
Decrease [qlco]
Risk [qlco]
Breast Cancer [neop]
postmenopausal [tmco]
Women [popg]
Estrogen [horm, phsu, strd]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Not [ftcn]
Increase [ftcn]
Risk [qlco]
Uterine Cancer [neop]
Not [ftcn]
Endometrial [spco]
Proliferation [patf]
Raloxifene [orch, phsu]
Rapidly [qlco]
Administration, Oral [topp]
Bioavailability [qnco]
Only [qnco]
Extensive [qlco]
First [qnco]
Past [tmco]
Effect [qlco]
Maximum Concentration [qnco]
Plasma [bdsu]
ng/mL [qnco]
Reach [orgf]
Raloxifene [orch, phsu]
More [ftcn]
bound [spco]
Plasma Proteins [aapp, bacs]
apparent [idcn]
distribution [idcn]
KG [geoa]
Clearance [qlco]
Half-Life [tmco]
Raloxifene [orch, phsu]
Multiple [qnco]
H+ [elii]
Oral [spco]
Dose [qnco]
Unchanged [fndg]
Urine [bdsu]
Urine [bdsu]
Glucuronide [carb]
conjugates [imft]
Serious Adverse Event [fndg]
Raloxifene [orch, phsu]
Fold [spco]
Increase [ftcn]
Risk [qlco]
Thromboembolic events [patf]
